Page last updated: 2024-11-13
inflachromene
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
inflachromene: has anti-inflammatory activity; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 49857340 |
CHEMBL ID | 1801580 |
SCHEMBL ID | 17518099 |
MeSH ID | M000601647 |
Synonyms (12)
Synonym |
---|
CHEMBL1801580 |
inflachromene |
908568-01-4 |
SCHEMBL17518099 |
5-hydroxy-9,9-dimethyl-15-phenyl-8-oxa-13,15,17-triazatetracyclo[8.7.0.0,.0,heptadeca-2(7),3,5,10-tetraene-14,16-dione |
AS-16939 |
10-hydroxy-7,7-dimethyl-2-phenyl-7,12b-dihydrochromeno[4,3-c][1,2,4]triazolo[1,2-a]pyridazine-1,3(2h,5h)-dione |
AKOS037643571 |
AC-36952 |
HY-113772 |
5-hydroxy-9,9-dimethyl-15-phenyl-8-oxa-13,15,17-triazatetracyclo[8.7.0.02,7.013,17]heptadeca-2(7),3,5,10-tetraene-14,16-dione |
CS-0063284 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (35)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1460206 | Stability in human liver microsomes assessed as compound remaining preincubated for 5 mins followed by NADPH addition measured after 30 mins LC/MS/MS method | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID1460191 | Anti-inflammatory activity in C57BL/6(B6) mouse model of CLP-induced sepsis assessed as decrease in serum IL-6 level at 10 mg/kg, ip administered daily for 9 days starting from 1 hr prior to CLP-induction by ELISA | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID604512 | Inhibition of MMP-7 mRNA expression in mouse RAW264.7 cells at 10 uM by RT-PCR analysis | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24 | Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand. |
AID604508 | Inhibition of RANKL-induced osteoclastogenesis in BALB/c mouse Bone marrow macrophages assessed as decrease in TRAP-positive cells after 1 hr by microplate reader assay | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24 | Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand. |
AID604511 | Inhibition of c-Src mRNA expression in mouse RAW264.7 cells at 10 uM by RT-PCR analysis | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24 | Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand. |
AID1460208 | Cmax in ICR mouse at 10 mg/kg, ip by LC/MS/MS method | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID1460203 | Inhibition of NF-kappaB p65 nuclear translocation in LPS-stimulated mouse RAW264.7 cells at 20 uM pretreated followed by LPS-induction by Hoechst 33342/TRITC staining based immunofluorescence microscopic method | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID1460205 | Stability in mouse liver microsomes assessed as compound remaining preincubated for 5 mins followed by NADPH addition measured after 30 mins LC/MS/MS method | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID604516 | Downregulation of RANKL-induced fra2 mRNA expression in mouse RAW264.7 cells at 10 uM by RT-PCR analysis | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24 | Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand. |
AID604507 | Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as decrease in TRAP-positive cells after 1 hr by microplate reader assay | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24 | Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand. |
AID1460196 | Inhibition of HMGB1 nuclear translocation in LPS-stimulated mouse RAW264.7 cells at 20 uM pretreated for 1 hr followed by LPS-induction measured after 2 hrs by Hoechst 33342/TRITC staining based immunofluorescence microscopic method | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID1460197 | Inhibition of HMGB1 nuclear translocation in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of IL-6 production at 10 uM pretreated for 1 hr followed by LPS-induction by Western blot analysis | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID1460190 | Anti-inflammatory activity in C57BL/6(B6) mouse model of CLP-induced sepsis assessed as increase in survival rate at 10 mg/kg, ip administered daily for 9 days starting from 1 hr prior to CLP-induction | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID1460202 | Inhibition of ERK phosphorylation in LPS-stimulated mouse RAW264.7 cells at 20 uM pretreated followed by LPS-induction by Western blot analysis | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID1460211 | Anti-inflammatory activity in C57BL/6(B6) mouse model of CLP-induced sepsis assessed as survival rate at 10 mg/kg, ip administered daily for 21 days starting from 1 hr prior to CLP-induction (Rvb = 10 %) | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID1460210 | Half life in ICR mouse at 10 mg/kg, ip by LC/MS/MS method | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID604513 | Inhibition of TRAP mRNA expression in mouse RAW264.7 cells at 10 uM by RT-PCR analysis | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24 | Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand. |
AID1460212 | Anti-inflammatory activity in C57BL/6(B6) mouse model of CLP-induced sepsis assessed as decrease in serum IL-6 level at 10 mg/kg, ip administered daily for 21 days starting from 1 hr prior to CLP-induction by ELISA | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID604514 | Downregulation of RANKL-induced c-fos mRNA expression in mouse RAW264.7 cells at 10 uM by RT-PCR analysis | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24 | Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand. |
AID1460193 | Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 10 uM in presence of LPS measured after 24 hrs by WST assay relative to control | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID604505 | Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 30 uM after day 1 by CCK-8 assay | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24 | Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand. |
AID1460198 | Inhibition of ICM-BP binding to recombinant human HMGB1 assessed as reduction in Cy5-azide incorporation pretreated for 60 mins followed by ICM-BP addition for 20 mins and subsequent UV light irradiation for 5 mins by fluorescence assay | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID604515 | Downregulation of RANKL-induced NFATc1 mRNA expression in mouse RAW264.7 cells at 10 uM by RT-PCR analysis | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24 | Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand. |
AID604509 | Inhibition of NFkappa signaling in mouse RAW264.7 cells assessed as reduction in RANKL-induced transcriptional activation on NF-kappaB by luciferase reporter gene assay | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24 | Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand. |
AID604518 | Inhibition of RANKL-induced p38 phosphorylation in mouse RAW264.7 cells at 10 uM by Western blot analysis | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24 | Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand. |
AID604506 | Cytotoxicity against mouse RAW264.7 cells assessed as cell viability at 30 uM after day 4 by CCK-8 assay | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24 | Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand. |
AID1460207 | Tmax in ICR mouse at 10 mg/kg, ip by LC/MS/MS method | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID1460192 | Inhibition of HMGB1 translocation from nucleus to cytosol in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of NO release at 10 uM measured after 24 hrs by Griess assay relative to control | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID604517 | Inhibition of RANKL-induced ERK phosphorylation in mouse RAW264.7 cells at 10 uM by Western blot analysis | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24 | Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand. |
AID1460209 | AUC in ICR mouse at 10 mg/kg, ip by LC/MS/MS method | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID1460201 | Inhibition of JNK phosphorylation at Thr183/Tyr185 resdiues in LPS-stimulated mouse RAW264.7 cells at 20 uM pretreated followed by LPS-induction by Western blot analysis | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID1460204 | Equilibrium aqueous solubility of the compound by microsol method | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID604504 | Inhibition of RANKL-induced osteoclastogenesis in mouse RAW264.7 cells assessed as TRAP-positive cells at 10 uM after 1 hr by microplate reader assay | 2010 | Journal of medicinal chemistry, Dec-23, Volume: 53, Issue:24 | Discovery of novel benzopyranyl tetracycles that act as inhibitors of osteoclastogenesis induced by receptor activator of NF-κB ligand. |
AID1460200 | Inhibition of MAPK p38 phosphorylation at Thr180/Tyr182 resdiues in LPS-stimulated mouse RAW264.7 cells at 20 uM pretreated followed by LPS-induction by Western blot analysis | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
AID1460195 | Inhibition of HMGB1 translocation from nucleus to cytosol in LPS-stimulated mouse RAW264.7 cells assessed as inhibition of TNF-alpha production at 10 uM measured after 4 hrs by ELISA relative to control | 2017 | Journal of medicinal chemistry, 01-12, Volume: 60, Issue:1 | Treatment of Sepsis Pathogenesis with High Mobility Group Box Protein 1-Regulating Anti-inflammatory Agents. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (10)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 7 (70.00) | 24.3611 |
2020's | 3 (30.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 24.64
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (24.64) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |